APIXABAN IN PATIENTS WITH ATRIAL FIBRILLATION- PATIENT CHARACTERISTICS OF THE LATIN AMERICA COHORT FROM A MULTINATIONAL CLINICAL TRIAL
Author(s)
Avezum A1, Bahit MC2, Hermosillo JA3, Zanetti FL4, Perafan P5, Juarez-Garcia A6, Vulcano C7, Cubillos LA8, Korenblat Donato BM9
1Dante Pazzanese Institute of Cardiology, São Paulo, Brazil, 2INECO Neurociencias, Rosario, Argentina, 3Insto Nacional de Cardiología, México, DF, Mexico, 4Universidad de La Frontera, Temuco, Chile, 5Fundación Valle del Lili, Cali, Colombia, 6Bristol-Myers Squibb Company, México, DF, Mexico, 7Bristol-Myers Squibb, Buenos Aires, Argentina, 8Pfizer, New Jersey, NJ, USA, 9Bristol-Myers Squibb, Wallingford, CT, USA
OBJECTIVES: Patients with Atrial fibrillation (AF), have a five-fold increase in the risk of stroke. Treatment for AF include stroke prevention therapy. Vitamin K antagonists (VKAs) have shown to prevent stroke in AF patients. Apixaban, a novel oral direct factor Xa inhibitor was studied in AF patients whom VKA therapy was unsuitable. Apixaban demonstrated clinical benefit in stroke or systemic embolism reduction without impacting the risk of major bleeding or intracranial hemorrhage. Patient characteristics of the Latin America (LA) cohort and overall population are presented. METHODS: Patients with AF at an increased risk for stroke and whom VKA therapy was unsuitable were randomized to receive apixaban (5 mg twice daily) or aspirin (81 to 324 mg) in a double blind trial. The study recruited from 36 countries from September 2007 through December 2009. Five countries were from LA: Argentina, Brazil, Chile, Colombia, and Mexico. Patient characteristics from the LA cohort, is presented relative to the overall trial population. RESULTS: Of
Conference/Value in Health Info
2015-09, ISPOR Latin America 2015, Santiago, Chile
Value in Health, Vol. 18, No. 7 (November 2015)
Code
CV2
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Cardiovascular Disorders